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CD22 Is Both a Positive and Negative Regulator of
B Lymphocyte Antigen Receptor Signal Transduction:
Altered Signaling in CD22-Deficient Mice
Shinichi Sato, Ann S. Miller, Makoto Inaoki, sialic acid–bearing ligands expressed by lymphocytes,
neutrophils, monocytes, and erythrocytes, as well asCheryl B. Bock, Paul J. Jansen, Mimi L. K. Tang,
nonhematopoietic cells (Aruffo et al., 1992; Engel et al.,and Thomas F. Tedder*
1993; Law et al., 1995; Powell et al., 1993; Sgroi et al.,Department of Immunology
1993; Stamenkovic et al., 1991). In vitro, CD22 ligationDuke University Medical Center
regulates B cell function (reviewed by Tedder et al.,Durham, North Carolina 27710
1997), and CD22 binding to T cells provides a costimula-
tory signal (Sgroi et al., 1995; Tuscano et al., 1996a).
Thus, CD22 may also regulate B cell migration or cell–Summary
cell interactions.
A positive signaling role for CD22 in B cell functionB cell activation following antigen receptor cross-link-
is suggested by studies where the addition of CD22ing can be augmented in vitro by ligation of cell surface
monoclonal antibodies (MAbs) to human B cell culturesCD22, which associates with the SHP1 protein tyrosine
stimulates proliferation directly or provides potent co-phosphatase. The targeted deletion of CD22 in mice
stimulation with anti-immunoglobulin antibodies, cyto-demonstrated that CD22 differentially regulates anti-
kines, or CD40 MAbs (Pezzutto et al., 1987; Tuscano etgen receptor signaling in resting and antigen-stimu-
al., 1996a). Treatment of B cells with a solid-phase CD22lated B lymphocytes. B cells from CD22-deficient mice
MAb prior to anti-immunoglobulin stimulation enhancesexhibited the cell surface phenotype and augmented
proliferation and reduces the concentration of anti-intracellular calcium responses characteristic of chron-
immunoglobulin needed for an equivalent responseically stimulated B cells, as occurs in SHP1-defective
without pretreatment (Doody et al., 1995). Since CD22mice. Thus, CD22 negatively regulates antigen recep-
MAb binding also enhances the increase in intracellulartor signaling in the absence of antigen. However, acti-
calcium flux ([Ca21]i) observed following surface immu-vation of CD22-deficient B lymphocytes by prolonged
noglobulin cross-linking, CD22 must contribute to theIgM cross-linking resulted in modest B cell prolifera-
earliest signaling cascades that occur during B cell acti-tion, demonstrating that CD22 positively regulates an-
vation (Pezzutto et al., 1988). Tyrosine phosphorylationtigen receptor signaling in the presence of antigen.
of CD22 also occurs rapidly following CD22 or antigen
receptor ligation (Leprince et al., 1993; Schulte et al.,
Introduction 1992; Tuscano et al., 1996b), suggesting that these two
receptors are closely linked. In fact, a small percentage
The balance among humoral immune responses, toler- (0.2%–2%) of surface immunoglobulin may physically
ance induction, and the development of autoimmunity associate with CD22 (Leprince et al., 1993; Peaker and
is regulated by signaling thresholds established through Neuberger, 1993). Consistent with a costimulatory role
B lymphocyte antigen receptors (Goodnow, 1996). for CD22 in augmenting B cell proliferation, a number of
These responses are further controlled by an array of effector molecules bind tyrosine-phosphorylated CD22
cell surface and cytoplasmic molecules that regulate via their src homology 2 (SH2) domains: p53/p56lyn,
antigen receptor signaling during B lymphocyte devel- p72syk, phosphatidylinositol (PI) 3-kinase, and phospholi-
opment and activation. Cell surface CD22 can regulate pase C-g1 (PLC-g1) (Law et al., 1996; Leprince et al.,
signal transduction through B lymphocyte antigen re- 1993; Tuscano et al., 1996b).
ceptors in vitro, but its in vivo function remains unde- The z140 amino acid cytoplasmic domain of CD22
fined (reviewed by Law et al., 1994; Tedder et al., 1997). includes six tyrosines that are targets for rapid phos-
CD22 is absent from the surface of pre-B cells and newly phorylation following surface immunoglobulin or CD22
emerging immunoglobulin M1 (IgM1) B cells, is present ligation (Schulte et al., 1992; Wilson et al., 1991). Two
at a low density on immature (B220loIgMhi) B cells, and regions of the CD22 cytoplasmic domain are homolo-
is fully expressed by mature (B220hiIgD1) B cells of the gous to the tyrosine-based activation motif (TAM) (re-
bone marrow (Erickson et al., 1996; Symington et al., viewed by Cambier, 1995; Weiss and Littman, 1994).
1982). In the periphery, CD22 is expressed at mature TAMs are found in multiple signaling receptors of immu-
levels on all B cell subsets (Erickson et al., 1996). CD22 nological importance, where they serve as platforms for
expression increases on mitogen-stimulated B cells, but the docking of p72syk/ZAP-70 kinases and may serve as
is lost during plasma cell differentiation. CD22 may platforms for src family tyrosine kinases. The cyto-
thereby provide regulatory signals during multiple plasmic domain of mouse CD22 also contains three re-
stages of B cell development. gions homologous to the tyrosine-based inhibition motif
CD22 is a member of the “sialoadhesin” subclass of (TIM), which provides docking sites for SH2 domains of
the immunoglobulin superfamily, whose members func- the SHP1 (previously termed SH-PTP1, PTP1C, SHP, or
tion as mammalian lectins (Engel et al., 1993; Kelm et HCP) protein tyrosine phosphatase (Matthews et al.,
al., 1994; Powell et al., 1993; Sgroi et al., 1993). Although 1992; Plutzky et al., 1992; Shen et al., 1991). TIMs are
the actual biological significance of CD22-mediated ad- found in transmembrane proteins involved in terminat-
hesion remains unknown, the two amino-terminal immu- ing signal transduction through other receptors, includ-
noglobulin domains of CD22 mediate interactions (Engel ing FcgRIIB and the inhibitory receptors p58 and p70 of
natural killer cells (Burshtyn et al., 1996; Fry et al., 1996).et al., 1995a; Law et al., 1995) with structurally diverse
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A negative signaling role for CD22 in B cell function has Table 1). However, there was a reduction in the number
of IgM1B220hi (36%, p < 0.01) and HSAloB220hi (55%, p <been suggested since tyrosine-phosphorylated CD22
associates with SHP1 following surface immunoglobulin 0.001) mature B cells in the bone marrow of CD222/2
mice (Figure 2A; Table 1). The number of IgM1B2201cross-linking (Campbell and Klinman, 1995; Doody et
al., 1995; Lankester et al., 1995; Law et al., 1996). While mature B cells in blood was also reduced (66%, p <
0.001) in CD222/2 mice (Figure 2B; Table 1). Therefore,CD22 is unique in containing both TAMs and TIMs, fur-
ther experiments examining the interactions of CD22 the number of mature B cells that recirculate through
the blood and bone marrow was reduced in CD222/2with the surface immunoglobulin complex and the role
of CD22-associated SHP1 in regulating antigen receptor mice.
Overall, the numbers of spleen IgM1B2201 B cellssignaling are needed to clarify the role of CD22 in regu-
lating B cell function. found in CD222/2 mice and wild-type littermates were
similar, although differences in the marginal zone sub-In the current study, CD22-deficient mice were gener-
ated to elucidate the function of CD22 in vivo. The population were apparent (Figures 2C and 3A; Table 1).
The number of marginal zone B cells (IgMhiCD21hi) wasphenotype of the CD22-deficient mice demonstrates
that CD22 expression differentially regulates signaling decreased by z50% (p < 0.04) in CD222/2 littermates
(Figure 3A; Table 1). This was consistent with the numberthrough the antigen receptor complex in resting and
activated B cells. of IgMhiIgDlo or IgMhiCD232 B cells being z40% lower
(p < 0.03) than in wild-type littermates, since these cells
include marginal zone B cells, immature B cells, andResults
B-1 B cells (Figure 3A; Table 1). Immunohistochemical
analysis of B cell subpopulations within the spleen dem-Generation of CD22-Deficient Mice
onstrated that the marginal zone appeared to be slightlyCD22-deficient mice were generated by mutation of the
wider, with a lower cell density than in CD222/2 mice,CD22 gene in the HM1 embryonic stem (ES) cell line
although the overall architecture and organization ofusing homologous recombination (Selfridge et al., 1992).
the spleen was similar between CD222/2 and wild-typeExons encoding a 59 portion of untranslated sequence,
littermates (data not shown). The decrease in marginalthe mRNA translation start site and leader peptide, and
zone B cells may relate to the low number of circulatinga portion of the first immunoglobulin domain were re-
B cells, since the marginal zone in normal mice containsplaced with a neomycin resistance marker that termi-
a high proportion of B cells that have recently emigratednates translation (Figures1A–1D). Following transforma-
from the circulation. The number of CD51B220lo B-1ation, two ES cell clones had the predicted mutation as
cells was normal in CD222/2 mice (Table 1). The numberdetermined by Southern blot analysis of restriction
of follicular or mantle zone B cells, defined as eitherendonuclease–digested genomic DNA. Chimeric mice
IgMloIgDhi or IgMloCD231, was slightly increased in CD22-generated from one ES cell clone transmitted the muta-
deficient mice (Figure 3A; Table 1). The decrease intion to their progeny. Mice heterozygous for the targeted
circulating B cells and spleen marginal zone B cellsallele were mated, and CD221/2 and CD222/2 mice were
correlated with higher numbers of B cells (43%, p < 0.01)obtained at the expected Mendelian frequency (Fig-
within peripheral lymph nodes of CD222/2 mice (Table 1).ure 1E). CD222/2 mice were deficient in cell surface
There was a 57% increase in the number ofCD22 expression as determined by immunofluores-
CD51B220lo B-1a cells within the peritoneum, with acence staining with the CY34 MAb specific for immuno-
compensatory decrease in the number of CD52B220higlobulin domains 1 and 2 (Law et al., 1995; van der
B-2 cells (Figure 2D; Table 1). Changes in the CD52Mac-Merwe et al., 1996) and the NIM-R6 MAb specific for
1lo B-1b population of cells were similar to those ob-membrane-proximal immunoglobulin domains (Law et
served for the B-1a population (data not shown). Whileal., 1995) (Figure 1F). Lymphocytes from CD221/2 mice
these results suggest a general increase in the numberreacted with the CY34 MAb with a mean fluorescence
of B-1 lineage cells in the peritoneum, these differencesintensity that was 59 6 4% (n 5 20) of wild-type lit-
were not statistically significant and the number oftermates (Figure 1F). Immunohistochemical staining of
IgM1B2201 B cells found within the peritoneal cavity offrozen sections of spleens from CD222/2 mice with the
CD222/2 mice was similar to that of wild-type littermatesCY34 and NIM-R6 antibodies did not reveal detectable
(Table 1).secreted, cell surface, or cytoplasmic CD22 protein
The effect of deleting CD22 was dose dependent,(data not shown). Therefore, the CD222/2 mice bear a
since the changes described above were also observed
genuine null mutation. CD22-deficient mice thrived and
in hemizygous mice, although the changes were always
reproduced as well as their wild-type littermates and did
more subtle (Table 1). In all cases, however, there were
not present any obvious anatomical or morphological
no obvious differences in the size (light scatter proper-
abnormalities during the first 4 months of life.
ties) of CD222/2 B lymphocytes isolated from bone mar-
row, blood, lymph nodes, or spleen when compared
B Cell Development in CD22-Deficient Mice with B lymphocytes from wild-type littermates (data not
CD222/2 mice had normal frequencies of CD431B220lo shown). There were no detectable changes in the devel-
pro-B cells and IgM2B220lo pro/pre-B cells in the bone opment or number of CD31, CD41, or CD81 T lympho-
marrow (Figure 2A; Table 1). The frequencies of IgM1 cytes or myelomonocytic cells in any of the above tis-
B220lo B cells were increased in CD221/2 (26%, p < 0.03) sues or thymus (data not shown). These data therefore
and CD222/2 mice (42%, p < 0.02), suggesting a small suggest that CD22 plays a modest functional role in the
development and tissue localization of B lymphocytes.increase in the number of immature B cells (Figure 2A;
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Figure 1. Targeted Disruption of the CD22 Gene
(A) Intron–exon organization of the CD22 gene containing 15 exons
based on the results of this study and those of Law et al. (1993).
Closed squares indicate untranslated sequence (UT) and open
squares indicate translated regions. Domains are indicated: leader
(L), immunoglobulin-like domains (Ig), transmembrane domain (TM),
and cytoplasmic (Cyto) domains.
(B) Restriction map of the targeted region of the CD22 gene. The
vertical arrow indicates a HincII restriction site that did not cut
efficiently, thereby generating two restriction fragments.
(C) Structure of the CD22 targeting vector showing the location of
the thymidine kinase (tk) and neomycin-resistance (neor ) genes in
the 59 to 39 orientation.
(D) Structure and restriction map of the predicted targeted allele.
Gene targeting in ES cells by homologous recombination would
result in acquisition of new EcoRI and HincII sites and loss of a
BstEII site, as indicated.
(E) Southern blot analysis of tail DNA from CD221/1, CD221/2, and
CD222/2 littermates digested with the listed enzymes and hybridized
with the 59 probe indicated in (B) and (D).
(F) Immunofluorescence analysis of CD22 expression by spleno-
cytes from CD221/1, CD221/2, and CD222/2 littermates with flow
cytometry analysis (solid lines). Dotted histograms represent immu-
nofluorescent staining with unreactive, isotype-matched control
MAbs. Secondary antibodies were FITC-conjugated goat anti–
mouse IgG1 antibodies for the CY34 MAb and phycoerythrin-conju-
gated goat anti–rat IgG antibodies for the NIM-R6 MAb.
CD22 Regulates IgM Expression Levels in the bone marrow, blood, spleen, and lymph nodes
was decreased substantially in CD222/2 mice (Figure 2;B cells from CD222/2 mice expressed a cell surface
phenotype that was reminiscent of weakly stimulated B Table 2). The lowest levels of IgM were observed on
bone marrow and circulating B cells from CD222/2 mice,cells. Cell surface levels of IgM on mature B220hi B cells
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Figure 3. B Lymphocyte Subpopulations Present in the Spleen of
CD22-Deficient Mice
(A) Splenocytes were isolated from wild-type, CD221/2, and CD222/2
littermates and examined by two-color immunofluorescence stain-
ing with flow cytometry analysis as described in Figure 2.Figure 2. Lymphocytes Present in Lymphoid Tissues of CD22-Defi-
(B) Flow cytometry analysis of MHC class II antigen (I-A) and CD44cient Mice
expression on spleen B cells from wild-type (broken lines), CD221/2Single cell suspensions of leukocytes were isolated from wild-type,
(thin unbroken line), and CD222/2 (thick lines) littermates. All resultsCD221/2, and CD222/2 littermates and examined by two-color immu-
are representative of those obtained with seven 2-month-old micenofluorescence staining with flow cytometry analysis. We analyzed
of each genotype.10,000 cells with the forward and side light scatter properties of
lymphocytes for each sample. Values represent the percentage of
the total gated lymphoid cell population that falls into the indicated
Thus, B cells from CD222/2 mice characteristically ex-quadrants. Populations of cells lacking surface antigen expression
press an IgMloIgDhiCD21/CD35lo-med phenotype with ele-were determined using unreactive isotype-matched MAbs as con-
trols. Horizontal broken lines in some histograms are provided for vated levels of class II, CD23, and CD44 reminiscent of
reference. These results are representative of those obtained with weakly stimulated B cells. This distinct phenotype is
six or seven 2-month-old mice of each genotype. equivalent to that of anergic B cells that have been
chronically exposed to soluble autoantigens in vivo
(Cooke et al., 1994; Cyster and Goodnow, 1995; Good-
which had z40% (p < 0.001) less IgM than wild-type B now et al., 1988).
cells (Table 2). B cells from CD221/2 mice expressed
intermediate surface IgM levels (Table 2). By contrast, Augmented [Ca21]i Response
B220loIgM1 immature B cells in the bone marrow of in CD22-Deficient B Cells
CD222/2 mice had slightly increased levels of IgM (Fig- The loss of CD22 dramatically altered early B cell signal-
ure 2A; Table 2). Cell surface IgD levels on mature B ing responses since splenic B cells from CD22-deficient
cells from the bone marrow, blood, and lymph nodes of mice demonstrated more acute increases in [Ca21]i fol-
CD222/2 mice were also lower, although to a lesser ex- lowing surface IgM cross-linking than B cells from wild-
tent than IgM (Table 2). The majority of spleen B cells type littermates (Figure 4A). Differences in [Ca21]i levels
from CD222/2 mice expressed low to medium levels of were largest when suboptimal concentrations (10 mg/
CD21/CD35, indicating that they were mature B cells ml) of anti-IgM antibodies were used, but [Ca21]i levels
(data not shown). B cells from CD22-deficient mice ex- in CD22-deficient B cells were also significantly in-
pressed levels of major histocompatibility complex creased at every timepoint after 170 s (p < 0.05 in three
(MHC) class II antigens (I-A) and CD44 that were signifi- experiments) when spleen B cells were stimulated by
cantly higher than wild-type B cells (Figure 3B; Table 2). optimal concentrations (40 mg/ml) of anti-IgM antibod-
CD23 levels were also higher on B cells from CD222/2 ies. B cells from CD221/2 mice showed intermediate
mice (Figure 3A; Table 2). However, CD18 expression responses. Similar results were obtained when CD19
levels and markers of cell activation such as CD86 (B7-2) was cross-linked with optimal concentrations (80 mg/ml)
of MAb (Figure 4B), with significantly increased [Ca21]iwere not increased in CD222/2 mice (data not shown).
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Table 1. Frequency and Numbers of B Lymphocytes in CD22-Deficient Mice
Percentage of Lymphocytes Number of Cells (3 106)a
Tissue Phenotype Wild Type CD221/2 CD222/2 Wild Type CD221/2 CD222/2
Bone marrow CD431B220lo 9 6 3 10 6 5 11 6 3
B220loIgM2 46 6 7 39 6 5 41 6 12
B220loIgM1 19 6 5 24 6 4* 27 6 7*
B220hiIgM1 14 6 4 16 6 4 9 6 3**
B220hiHSAlo 22 6 6 25 6 6 10 6 4**
Blood B2201IgM1 51 6 5 45 6 9 29 6 5** 6.7 6 0.8 6.4 6 1.4 2.3 6 1.1**
Spleen B2201IgM1 48 6 4 50 6 5 54 6 4** 44 6 10 47 6 14 43 6 16
IgMloIgDhi 21 6 5 24 6 6 30 6 5** 19 6 6 23 6 9 24 6 9
IgMhiIgDlo 8.0 6 3.0 7.3 6 2.1 5.5 6 0.8* 7.8 6 4.6 6.8 6 2.6 4.4 6 2.1*
IgMhiCD21hi 3.0 6 1.2 2.7 6 1.5 1.9 6 0.8* 2.9 6 1.7 2.5 6 1.6 1.5 6 0.9*
B220loCD51 2.0 6 0.5 2.5 60.8 2.6 6 0.5 2.2 6 1.0 2.8 6 2.0 2.6 6 2.4
Lymph nodes B2201IgM1 14 6 3 17 6 4 20 6 5** 0.7 6 0.2 1.0 6 0.6 1.0 6 0.3**
Peritoneum B2201IgM1 59 6 13 67 6 10 61 6 12 1.4 6 0.7 1.8 6 1.0 1.6 6 0.7
B220loCD51 31 6 5 42 6 16 49 6 14** 0.7 6 0.3 1.1 6 0.5 1.1 6 0.7
B220loIgDlo 53 6 8 67 6 8* 64 6 9*
B220hiCD52 37 6 3 36 6 10 25 6 7** 0.9 6 0.4 1.0 6 0.6 0.6 6 0.3
B220hiIgDhi 16 6 2 13 6 7 12 6 6
Values represent mean (6 SD) results obtained from six or seven different 2-month-old mice. Numbers represent the percentage of lymphocytes
(based on side and forward light scatter properties) expressing the indicated cell surface markers as determined in Figures 2 and 3 using
two-color immunofluorescence staining.
a B cell numbers were calculated based on the total number of cells harvested from the indicated tissues. For blood, the values indicate the
number of cells per milliliter.
Asterisk, the percentage or number of cells was significantly different than in wild-type littermates, p , 0.05; double asterisk, p , 0.01, as
determined using the paired Student’s t test.
levels at timepoints between 190 and 330 s (p < 0.05 in other causes. By contrast, the proliferation of purified
B cells from CD222/2 mice in response to LPS, CD38,three experiments). However, these differences were
not observed when suboptimal concentrations (40 mg/ and CD40 was similar to that of wild-type littermates
over a range of mitogen concentrations (Figure 5). Prolif-ml) of anti-CD19 MAb was used. It is unlikely that the
small changes in B lymphocyte subpopulations noted eration in response to CD40 ligation plus IL-4 was higher
in CD222/2 mice at all CD40 concentrations (112 6 77%earlier could result in such dramatic changes in [Ca21]i
responses. Therefore, the exaggerated calcium re- at 1 mg/ml, p < 0.01 in four experiments). Proliferation
at low concentrations of anti-CD38 MAb (plus IL-4) wassponse to surface IgM cross-linking in CD22-deficient
B cells is likely to result directly from alterations in the also higher (134 6 59% at 0.1 mg/ml, p < 0.002 in four
activation or maturation states of these cells or their
signaling capacity. Table 2. IgM and IgD Expression Levels in CD22-Deficient Mice
Expression Relative toB Cell Proliferation in CD22-Deficient Mice Wild-Type Mice
The effect of CD22 loss on B cell responses to IgM, (percent 6 SD)
interleukin-4 (IL-4), lipopolysaccharide (LPS), CD38, and
Antigen Source of B Cells CD221/2 CD222/2CD40 was examined, since each of these mitogenic
IgM Bone marrow B220lo 105 6 26 111 6 10**signals activates B cells through divergent signaling
B220hi 89 6 19 62 6 12**cascades. The proliferative response of purified B cells
Blood B2201 66 6 12* 57 6 30*from CD22-deficient mice to cross-linking of surface
Spleen B2201 97 6 22 78 6 16**
IgM was significantly lower (45 6 15% at 20 mg/ml, p < Lymph node B2201 96 6 20 64 6 14**
0.0005 in four experiments) over a range of antibody IgD Bone marrow IgMlo 95 6 15 73 6 5**
concentrations (Figure 5). Similar results were obtained Blood IgM1 104 6 7 83 6 9*
Spleen IgMlo 103 6 12 100 6 8when the B cells were activated using suboptimal con-
Lymph node IgM1 101 6 18 90 6 14*centrations of anti-IgM antibodies (5 mg/ml) with in-
CD23 Spleen IgMlo 138 6 54* 149 6 75*creasing concentrations of IL-4 added to the cultures
Class II Spleen IgM1 109 6 19 146 6 22**
(36 6 13% at 50 U/ml, p < 0.0007 in four experiments) CD44 Spleen IgM1 117 6 23 139 6 26**
(Figure 5). The decrease in proliferation on day 3 did
Relative cell surface receptor densities were determined by compar-not result from changes in the kinetics of the maximal
ing the channel numbers of the mean linear fluorescence intensity
proliferative response (data not shown). Proliferation of between B cells from wild-type and CD221/2 or CD222/2 mice. Val-
CD222/2 and wild-type B cells in response to antigen ues represent the mean percentage of wild-type expression levels
receptor cross-linking with intact rabbit anti–mouse IgM obtained from five to seven mice of each genotype. All samples
were stained in parallel and analyzed sequentially by flow cytometryantibodies paralleled that obtained with F(ab9)2 antibod-
with identical instrument settings as shown in Figures 2 and 3.ies (data not shown). This suggests that negative signal-
Asterisk, differences between test and wild-type mice were signifi-ing through Fc receptors is not affected by the loss of
cant, p , 0.05; double asterisk, p , 0.01.
CD22 and that the decrease in proliferation results from
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Figure 4. Signal Transduction through Sur-
face IgM and CD19 in B Cells from CD22-
Deficient Mice
Splenocytes from wild-type, CD221/2, and
CD222/2 mice were isolated, loaded with
indo-1, and stained with FITC-labeled anti-
B220 MAb. B cells were examined for relative
[Ca21]i levels by flow cytometry after gating
on the B2201 population of cells. Suboptimal
or optimal concentrations of antibodies reac-
tive with IgM (A) or CD19 (B) were added to
the cell mixtures at the indicated times
(arrows). An increase in [Ca21]i over time is
shown as an increase in the ratio of indo-1
fluorescence. Values represent the ratios of
fluorescence intensity of cell populations
after MAb treatment relative to the fluores-
cence intensity of untreated cells. These re-
sults are representative of those obtained
from three littermate pairs of mice.
experiments) in CD22-deficient B cells (Figure 5). Similar 1990). However, following overnight activation with anti-
IgM antibodies, B cells from CD222/2 mice generatedresults were obtained in all cases with unfractionated
splenocytes (data not shown). Proliferation of B cells acute increases in [Ca21]i levels following surface IgM
cross-linking, while B cells from wild-type mice did notfrom CD221/2 mice varied considerably among mice, but
ranged between that of wild-type and CD22-deficient B generate detectable changes in [Ca21]i levels (Figure 6).
These differences did not result from different densitiescells (data not shown). Therefore, the loss of CD22 had
a selective negative effect on signaling through the anti- of cell surface IgM, since both CD222/2 B cells and wild-
type B cells expressed identical levels of IgM followinggen receptor complex, while minimal or positive effects
were observed when the B cells were stimulated with overnight culture (data not shown). Furthermore, anti-
body binding to as little as 2%–10% of membrane IgMother mitogens.
leads to inactivation of the signal transducing ability of
membrane immunoglobulin (Cambier et al., 1988). BDefective Desensitization of IgM Signaling
cells activated with LPS generated changes in [Ca21]iin CD222/2 B Cells
levels that were similar to those observed for B cellsSince CD222/2 mice exhibit a phenotype compatible
that had not been activated in culture (Figures 4A andwith anergic B cells, it was not clear whether the defec-
6). Therefore, even though the antigen receptor complextive proliferative response observed in response to anti-
in CD222/2 mice is more efficient at initiating changesIgM triggering was a direct consequence of loss of a
in Ca21 mobilization, signal transduction through theCD22 costimulatory function, due to small differences
antigen receptor complex in CD222/2 mice was not de-in the activation status of the B cells, or a secondary
sensitized following surface IgM cross-linking.consequence of developmental abnormalities leading to
partial desensitization of the antigen receptor–induced
proliferative pathway. This was addressed by examining B Cell Differentiation in Mice that Lack CD22
Serum immunoglobulin levels in nonimmunized micethe ability of membrane IgM ligation to desensitize Ca21
mobilization following Bcell activation. In normal B cells, were determined to assess the influence of the CD22
deficiency on B cell differentiation. On average, higherantigen receptor ligation leads to homologous desensiti-
zation of membrane immunoglobulin and heterologous levels of IgM (40%, p < 0.05) and IgA (200%, p < 0.01)
were found in CD22-deficient mice (Figure 7). However,desensitization of other cell surface receptors, making
them incapable of transducing Ca21 mobilizing signals serum IgG levels of all isotype were not significantly
affected by the loss of CD22. The elevated serum IgM(Lazarus et al., 1991; Rigley et al., 1989; Rijkers et al.,
CD22 Regulates B Lymphocyte Signaling
557
to DNP-KLH that were similar to those of wild-type mice
(Table 3). Following secondary challenge with DNP-KLH,
germinal centers in the spleens of CD22-deficient mice
were similar to those of wild-type littermates in both
frequency and size (data not shown). Therefore, CD22
was not required for isotype switching or T cell–B cell
interactions in the generation of humoral immune re-
sponses.
Discussion
The generation of CD22-deficient mice provides consid-
erable insight into the role of CD22 in vivo and demon-
strates directly that CD22 regulates cell surface antigen
receptor signaling. Expression levels of cell surface IgM
were significantly reduced on mature B cells from the
bone marrow, blood, spleen, and lymph nodes of
CD222/2 mice, but not for immature B cells in the bone
marrow (Figure 2; Table 2). Spleen B cells from CD222/2
mice were generally IgMloIgDhiCD21/CD35lo-med, with in-
creased expression of MHC class II antigens, CD23, and
CD44 (Figure 3; Table 2). Although this distinct pheno-
type suggests B cell activation, the B cells did not ap-
pear to be overtly activated since B cell size was the
same as in wild-type mice (data not shown). The IgMlo
IgDhiCD21/CD35lo-med phenotype is equivalent to that of
anergic B cells that have been chronically exposed to
soluble autoantigens in vivo (Cooke et al., 1994; Cyster
and Goodnow, 1995; Goodnow et al., 1988). Decreased
expression of cell surface IgM is also observed in B cells
from mice that overexpress CD19 (S. S. and T. F. T.,
unpublished data; Engel et al., 1995b; Sato et al., 1995)
and in SHP1-defective B cells from motheaten miceFigure 5. Proliferation of CD22-Deficient B Cells in Response to
(Cyster and Goodnow, 1995; Pani et al., 1995; SchultzMitogenic Signals
et al., 1993; Sidman et al., 1978; Tsui et al., 1993). Down-Spleen B cells (2 3 105 per well) from CD222/2 mice and wild-type
regulated surface IgM levels in SHP1-defective moth-littermates were purified by complement-mediated lysis of T cells.
B cells were cultured for 72 hr with the indicated amounts of anti- eaten mice is a consequence of augmented transmem-
IgM antibodies, LPS, or anti-CD40 MAbs. B cells were also cultured brane signaling through the B cell antigen receptor
with anti-IgM antibodies (5 mg/ml) plus the indicated concentrations complex (Cyster and Goodnow, 1995; Pani et al., 1995).
of IL-4 or IL-4 (100 U/ml) plus the indicated concentrations of anti-
The phenotype of mature CD222/2 B cells may also ex-CD38 or anti-CD40 MAbs. Proliferation was assessed by the incor-
plain their decrease within the bone marrow and circula-poration of labeled thymidine (1 mCi per well) added during the last
tion and their commensurate increase within peripheral16 hr of culture. Values represent the mean values (6 SD) obtained
from triplicate cultures. These results are representative of those lymph nodes (Table 1). Rather than reflecting a defi-
obtained in four independent experiments. ciency in maturation, preliminary studies suggest that
the activation status of CD222/2 B cells promotes their
migration into peripheral lymphoid tissues. Therefore,
these results demonstrate a strong association betweenlevels in CD22-deficient mice may correlate with the
small increase in B-1 cell numbers (Fo¨rster and Rajew- CD22 function and antigen receptor expression levels
and suggest that B cells from CD22-deficient mice maysky, 1987).
The influence of CD22 deficiency on the humoral im- be enduring enhanced antigen receptor signaling in the
absence of antigen, as occurs in SHP1-defective mice.mune response was assessed by immunizing mice with
a T cell–dependent antigen, 2,4-dinitrophenol-conjugated B cells from CD22-deficient mice generated [Ca21]i
increases that were dramatically higher than those ofkeyhole limpet hemocyanin (DNP-KLH), a T cell–inde-
pendent type2 antigen,DNP-Ficoll, and a T cell–independ- wild-type littermates in response to cross-linking of sur-
face IgM (Figure 4). Exaggerated [Ca21]i responses haveent type 1 antigen, 2,4,6-trinitrophenol (TNP)-conju-
gated LPS. Following immunization, CD22-deficient also been observed with SHP1-defective B cells at high
antigen concentrations (Cyster and Goodnow, 1995).mice mounted primary IgM responses that were higher
than, but not significantly different from, those of wild- However, CD22-deficient B cells appear particularly
sensitive to antigen receptor signaling because subopti-type mice (Table 3). IgG1, IgG2a, IgG2b, IgG3, and IgA
responses of CD22-deficient mice were not significantly mal antigen receptor cross-linking generated [Ca21]i re-
sponses equivalent to optimal responses in wild-typedifferent from those of wild-type littermates. CD22-defi-
cient mice generated secondary IgM and IgG responses mice (Figure 4). Since PLC-g phosphorylation, [Ca21]i
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Figure 6. Antigen Receptor Desensitization
in Activated B Cells from CD22-Deficient
Mice
Splenocytes from wild-type and CD222/2
mice were cultured overnight with anti-IgM
antibodies or LPS, loaded with indo-1, and
stained with FITC-labeled anti-B220 MAb. B
cells were examined for relative [Ca21]i levels
by flow cytometry after gating on the B2201
population of cells as in Figure 4. Anti-IgM
antibodies (10 mg/ml) were added to the cell
mixtures at the indicated times (arrows).
mobilization, and protein kinase C activation in response the absence of CD22 may mimic the absence of SHP1
and permit chronic tyrosine phosphorylation of the anti-to antigen receptor ligation are downstream of tyrosine
kinase activation (Hempel et al., 1992; Lane et al., 1991; gen receptor in the absence of antigen.
B cell proliferation in CD22-deficient mice was signifi-Padeh et al., 1991; Roifman and Wang, 1992), the loss
of CD22 may augment upstream signaling events such cantly diminished in response to IgM ligation over a
broad range of concentrations (Figure 5). The loss ofas antigen receptor or kinase phosphorylation, which in
turn leads to the enhanced mobilization of Ca21 immedi- CD22 appeared specifically to diminish surface IgM–
induced proliferation, since CD22-deficient B cell re-ately following antigen receptor ligation. As a specific
example, the absence of CD22 may result in augmented sponses to LPS, CD40, and CD38 plus IL-4 were not
very different from those of wild-type B cells (Figure 5).phosphorylation of PLC-g1, since CD22 is reported to
serve a central role in the formation of a multimolecular
complex of SHP1 with PLC-g1 and p72syk (Law et al.,
1996). Therefore PLC-g1 phosphorylation may not be
negatively regulated by SHP1 in CD222/2 B cells. These
results emphasize a negative role for CD22 in regulating
signaling through the antigen receptor complex.
Persistent low level phosphorylation of the antigen
receptor complex would explain why B cells from
CD222/2 mice generated augmented [Ca21]i responses
and why CD22-deficient B cells manifest a phenotype
that occurs in B cells chronically exposed to soluble
autoantigens in vivo (Cooke et al., 1994; Cyster and
Goodnow, 1995; Goodnow et al., 1988). Protein tyrosine
kinases that associate with the antigen receptor com-
plex in resting B cells are likely to tyrosine phosphorylate
antigen receptor subunits at low levels in the absence
of antigen (Burkhardt et al., 1991; Hutchcroft et al., 1992;
Yamanashi et al., 1993). ZAP-70 in T cells is also associ-
ated with constitutively tyrosine-phosphorylated T cell
antigen receptor z chains in vivo (van Oers et al., 1993,
1994). In resting B cells, SHP1 normally inhibits this
process and maintains a tyrosine-dephosphorylated an-
tigen receptor complex (Pani et al., 1995). Enzymatically
active SHP1 physically and functionally associates with
the B cell antigen receptor complex in resting B cells
through interactions that are not mediated by SHP1 SH2
domains binding phosphotyrosines of the antigen re-
ceptor complex (Pani et al., 1995). A small portion of
CD22 also physically associates with the B cell antigen
receptor complex, which may berapidly phosphorylated
following antigen receptor signaling (Leprince et al.,
1993; Peaker and Neuberger, 1993). Therefore, it is rea-
sonable to postulate that spontaneous activation of the
Figure 7. Serum Immunoglobulin Levels of 2-Month-Old CD221/1,
B cell antigen receptor complex results in low level tyro- CD221/2, and CD222/2 Mice
sine phosphorylation of proximalCD22 molecules. SHP1 CD221/1 mice are indicated by open circles, CD221/2 mice by
binds to phosphorylated CD22, thereby maintaining an shaded circles, and CD222/2 by closed circles. Immunoglobulin lev-
enzymatically active phosphatase within the antigen re- els of eight paired littermates were determined by isotype-specific
ELISA. Bars represent mean serum immunoglobulin levels.ceptor complex of resting B cells. In CD222/2 B cells,
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Table 3. Humoral Immune Responses in CD22-Deficient Mice
Relative Antibody Level (OD405 6 SEM)Immunoglobulin Mouse
Antigen Isotype Genotype Day 0 Day 7 Day 14 Day 28a
TNP-LPS IgM Wild type 26 6 4 565 6 117 263 6 62
CD221/2 17 6 4 600 6 175 316 6 109
CD222/2 28 6 4 633 6 76 325 6 44
DNP-Ficoll IgM Wild type 35 6 8 629 6 237 696 6 295
CD221/2 17 6 2 1016 6 243 753 6 198
CD222/2 43 6 6 815 6 109 905 6 169
IgG1 Wild type 2 6 4 126 6 73 513 6 325
CD221/2 2 6 2 358 6 112 763 6 247
CD222/2 1 6 2 132 6 34 426 6 141
DNP-KLH IgM Wild type 10 6 1 457 6 83 501 6 112 646 6 135
CD221/2 18 6 9 646 6 141 785 6 125 996 6 112
CD222/2 20 6 5 559 6 126 537 6 158 999 6 92
IgG1 Wild type 8 6 2 758 6 104 1091 6 27 1415 6 29
CD221/2 9 6 2 717 6 59 1058 6 34 1376 6 44
CD222/2 4 6 3 528 6 115 994 6 41 1348 6 19
Relative antibody levels of 2-month-old mice were determined by isotype-specific ELISA. Values represent mean serum antibody levels from
four to six paired littermates. These results are representative of those obtained for IgG2a, IgG2b, IgG3, and IgA in immunization with DNP-Ficoll
and DNP-KLH and are representative of those obtained for IgG1, IgG2a, IgG2b, IgG3, and IgA for immunization with TNP-LPS.
a Mice immunized with DNP-KLH were challenged with antigen again on day 21 so that secondary antibody responses could be assessed on
day 28.
Likewise, the overnight activation of CD222/2 B cells could be correct, since the presence of multiple phos-
phorylated tyrosine residues as well as TAM and TIMthrough ligation of cell surface IgM did not result in anti-
motifs in CD22 suggests that CD22 intersects multiplegen receptor desensitization, while signaling through
signaling cascades with the overall outcome dependingIgM on wild-type B cells was completely desensitized
on the relative strengthof individual signaling pathways.(Figure 6). These two defects in CD222/2 B cell function
The current studies demonstrate that CD22 functionmay result from common causes, since both receptor
is closely linked with antigen receptor expression anddesensitization and proliferation are downstream of ty-
signaling and that CD22 may control basal signal trans-rosine kinase activation (Brunswick et al., 1994). These
duction thresholds initiated through the B lymphocyteresults demonstrate a role for CD22 in the positive regu-
antigen receptor in resting B cells and during B celllation of signaling events through the antigen receptor in
proliferation in response to antigen. These studies alsoresponse to persistent ligation by antigen. By contrast,
suggest that CD22 and SHP1 function through overlap-SHP1-defective B cells are hyper-responsive tosubopti-
ping pathways to regulate B cell signaling. Based onmal concentrations of mitogenic anti-IgM antibodies,
the current studies, inherited polymorphisms in CD22but proliferate normally in response to LPS stimulation
or other linked regulatory molecules may vary the strin-(Pani et al., 1995). This suggests that CD22 and SHP1
gency of tolerance or response thresholds in outbredplay a different role following antigen receptor ligation.
human populations. This may also be a particularly im-Antigen receptor ligation disrupts the association be-
portant factor for the proliferative capacity of human Btween SHP1 and the antigen receptor complex, while
cell malignancies that display considerable hetero-inducing tyrosine phosphorylation of SHP1 as well as a
geneity in expression of CD22. CD22 is only weaklylarge portion of cellular CD22 (Pani et al., 1995; Schulte
expressed by B lineage chronic lymphocytic leuke-et al., 1992). Two closely related models could therefore
mias, but is expressed by a large percentage of B lin-explain diminished signaling in CD22-deficient B cells
eage lymphomas and leukemias (Do¨rken et al., 1986;in response to prolonged incubation with anti-immuno-
Schwarting et al., 1985). In fact, CD22 expression onglobulin antibodies. It is possible that SHP1 is recruited
hairy cells is markedly increased when compared withaway from the antigenreceptor by phosphorylated CD22
normal B cells (Do¨rken et al., 1986; Schwarting et al.,molecules not associated with the antigen receptor
1985). Thus, alterations in CD22 function or expressioncomplex. In CD22-deficient B cells, SHP1 would remain
could contribute substantially to autoimmunity or otherassociated with the B cell antigen receptor and down-
diseases in which B cell function is dysregulated.regulate tyrosine phosphorylation. Alternatively, CD22
may function as a costimulatory molecule that functions
Experimental Proceduresin close and specific association with the antigen recep-
tor complex. When strong positive signals aregenerated Production of CD22-Deficient Mice
through the antigen receptor complex, positive costimu- DNA encoding the CD22 gene was isolated from a genomic library
derived from 129/Sv strain mice using a cDNA probe that encodedlatory interactions among CD22, surface IgM, p72syk,
the first two immunoglobulin domains of CD22 as previously de-p53/p56lyn, PI 3-kinase, and PLC-g1 may result in prolif-
scribed (Zhou et al., 1991). Fragments of genomic DNA containingerative signals that surpass the negative regulatory ef-
the 59 end of the CD22 gene were mapped for restriction endonucle-
fects of SHP1. This mechanism is consistent with the ase sites, and exons were localized (Figure 1A) as described (Law
observation that ligation of CD22 alone can induce B et al., 1993). The targeting vector was constructed using a pBlue-
script SK (Stratagene, La Jolla, CA) based targeting vector (p594;cell proliferation (Tuscano et al., 1996a). Both models
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provided by Dr. D. Milstone, Brigham and Women’s Hospital, Bos- erythrocytes were lysed after staining using the Coulter whole blood
Immuno-Lyse kit as detailed by the manufacturer (Coulter, Inc.,ton, MA). Fragments of genomic DNA containing the CD22 gene
and flanking sequences were sequentially inserted into the targeting Miami, FL). Cells were washed and analyzed on a FACScan flow
cytometer (Becton Dickinson, San Jose, CA). Cells with the forwardvector flanking the neomycin resistance marker from pGK–neo
poly(A) (Stratagene) that contained the PGK promoter and poly(A) and side light scatter properties of mononuclear cells were analyzed
for each sample with fluorescence intensity shown on a four-decadesignal sequence. The 59 end of the targeting vector was generated
from a 1.4 kb HindIII fragment of DNA that contained the 59 end of log scale. Fluorescence contours are shown as 50% log density
plots. Positive and negative populations of cells were determinedexon 1 and upstream DNA that was inserted proximal to the pMC1-
HSV–TK gene (Figure 3C). The 39 end of the targeting vector was using unreactive isotype-matched MAbs (Coulter, Inc.) as controls
for background staining. Background levels of staining were deline-obtained from a 3.2 kb fragment of DNA that started at the HincII
site in exon 4 that encodes the first immunoglobulin domain and ated using gates positioned to include 98% of the control cells.
also contained exon 5. The vector was linearized using a unique
KpnI restriction site that flanked the 39 end of the CD22 gene insert. Measurement of [Ca21]i
HM-1 ES cells (provided by Dr. D. W. Melton, The University of Spleen cells were isolated at room temperature, washed, and resus-
Edinburgh, United Kingdom) were transfected with linearized plas- pended at 107 per milliliter in RPMI 1640 medium containing 5%
mid DNA and selected for G418 resistance as described (Selfridge (v/v) bovine calf serum, 10 mM HEPES (all from Sigma, St. Louis,
et al., 1992). Genomic DNA from individual selected clones was MO) and loaded with 1 mM indo-1-AM ester (Molecular Probes,
digested with EcoRI plus KpnI and hybridized with a 900 bp probe Eugene, OR) at 378C for 30 min. The cells were washed and stained
external to the targeting vector to screen for homologous recombi- with FITC-conjugated anti-B220 MAb for 30 min at room tempera-
nation as described (Zhou et al., 1994). A DNA restriction fragment ture, washed, and resuspended at 2 3 106 cells per milliliter. For
of 10 kb corresponded to the wild-type allele, while a new 4.8 kb analysis, the ratio of fluorescence (525/405 nm) of B2201 cells (1.5 3
fragment resulted from the targeted allele. Two clones containing 106 cells in 0.75 ml samples) was determined using a FACStar flow
both alleles were identified out of 1025 G418-resistant ES colonies cytometer (Becton Dickinson). Baseline fluorescence ratios were
screened. The structure of the targeted allele was further analyzed collected for 1 min before specific MAbs were added. The final
by HincII and BstEII digestion using the 59 flanking probe. DNA concentrations of antibodies were as follows: MB19-1, 40 or 80 mg/
restriction fragments of 9.6 and 5.4 kb corresponded to the wild- ml; affinity-purified goat F(ab9)2 antibody fragments to mouse IgM,
type HincII allele because of an inefficiently cut HincII site within 10 or 40 mg/ml (Cappel, Durham, NC). Fluorescence ratios were
exon 4, while a new 3.3 kb fragment resulted from the targeted collectedat real time for 7 min followingaddition of antibody.Results
allele. DNA restriction fragments of 9.4 and 2.6 kb corresponded to were plotted as the fluorescence ratio at 20 s intervals with the
the wild-type BstEII allele, while 9.4 and 9.6 kb fragments resulted background subtracted. An increase in the fluorescence ratio indi-
from the targeted allele. The Southern blot pattern obtained was cates an increase in [Ca21]i. Changes in [Ca21]i levels were also
consistent with the appropriate predicted mutation indicating that measured in B cells cultured overnight in culturemedium (RPMI1640
detrimental recombinations did not occur in the vicinity of the de- medium containing 10% fetal bovine serum, 10 mM L-glutamine,
sired homologous recombination. Targeted ES cell clones were in- antibiotics, 55 mM mercaptoethanol) with 20 mg/ml LPS or 20 mg/
jected into 3.5-day-old C57BL/6 blastocysts, which were then trans- ml goat F(ab9)2 anti–mouse IgM antibodies. Cells were washed and
ferred to foster mothers. Chimeric mice from one ES cell clone loaded with indo-1-AM ester, and changes in [Ca21]i were measured
transmitted the mutation to their progeny. Mice carrying the mutant after treating the cells with 10 mg/ml goat F(ab9)2 anti–mouse IgM
CD22 allele were intercrossed and the genotype of the offspring antibody.
was determined by Southern blot analysis of DNA obtained from
tail biopsies.
B Cell Proliferation
Spleen B cells were purified (>98% B2201) by complement-medi-
Antibodies and Immunofluorescence Analysis ated lysis of T cells with anti–T cell receptor (H57-597; provided by
Antibodies used in this study included the following: anti-CD22 Dr. R. Kubo, Denver, CO), anti-Thy1.2 (HO-13-4, ATCC clone TIB99),
(CY34.1.2; American Type Culture Collection [ATCC], Bethesda, MD; andanti-CD3 MAbs. B cells werecultured in0.2 ml of culture medium
clone TIB163; Symington et al., 1982); anti-CD22 (NIM-R6; provided in 96-well flat-bottom tissue culture plates with LPS (E. coli serotype
by Dr. M. Parkhouse, Pirbright, United Kingdom); anti-CD19 0111:B4; Sigma) as indicated for 72 hr. B cells were also stimulated
(MB19-1, IgA; Sato et al., 1996); biotinylatedor fluorescein isothiocy- with F(ab9)2 fragments of goat anti–mouse IgM antibodies (Cappel)
anate (FITC)-conjugated anti-B220 (CD45RA, RA3-6B2; Coffman either alone or in the presence of recombinant mouse IL-4 (100 U/ml;
and Weissman, 1981); anti-I-A (M5/114.15.2; ATCC clone TIB120); Pharmingen), anti-CD38 MAb (NIMR5; provided by Dr. M. Howard,
anti-CD21/CD35 (7E9; provided by Dr. T. Kinoshita, Osaka, Japan); DNAX Corp., Palo Alto, CA) in the presence of IL-4 (100 U/ml), anti-
anti-heat-stable antigen (M1/69; Pharmingen, San Diego, CA); anti- CD40 MAb (1C10; provided by Dr. M. Howard) either alone or in
CD43 (S7; Pharmingen); anti-CD18 (C71/16; Pharmingen); anti-CD44 the presence of IL-4 (100 U/ml). Proliferation was assessed by the
(IM7.8.1; Caltag, South San Francisco, CA); anti-CD5 (53-7.313; incorporation of 3H-labeled thymidine (1 mCi per well) added during
ATCC clone TIB104); anti-CD23 (B3B4; provided by Dr. D. Conrad, the last 16 hr of culture, followed by scintillation counting. All treat-
Virginia Commonwealth University, Richmond, VA); anti-B7-2 (GL1; ments were carried out in triplicate cultures.
Pharmingen); anti-Syndecan-1 (281-2; Pharmingen); anti-Mac-1
(M1/70.15; Caltag);anti-CD3 (145-2C11; ATCC clone CRL1975); anti-
Immunization of MiceCD4 (H129.19; Pharmingen); anti-CD8a (53-6.7; Pharmingen); and
We intraperitoneally immunized 2-month-old mice with 100 mg ofanti–mouse IgD allotype b (Southern Biotechnology Associates Inc.,
DNP-KLH (Calbiochem-Novabiochem Corp., La Jolla, CA) in com-Birmingham, AL) MAbs. Phycoerythrin-conjugated goat F(ab9)2 anti–
plete Freund’s adjuvant and boosted them 21 days later. Also, micerat IgG antibodies absorbed with mouse immunoglobulin (GIBCO
were immunized intraperitoneally with 25 mg of DNP-Ficoll (Bio-BRL, Gaithersburg, MD); FITC-conjugated goat anti–mouse IgG1
search Technologies, San Rafael, CA) or 50 mg of TNP-LPS (Sigma)(Fisher Scientific, Fair Lawn, NJ); and goat anti–mouse IgM isotype–
in saline. Mice were bled before and after immunization.specific antibodies (Southern Biotechnology Associates Inc.) were
also used. Phycoerythrin-conjugated streptavidin (Fisher Scientific)
was used to reveal biotin-coupled MAb staining. Mouse Immunoglobulin Isotype–Specific ELISAs
Enzyme-linked immunosorbent assays (ELISAs) were carried out asSingle cell suspensions of lymphocytes from the spleen, bone
marrow, peripheral lymph nodes, thymus, and peritonealcavity were described previously using affinity-purified mouse IgM, IgG1, IgG2a,
IgG2b, IgG3, and IgA MAbs (Southern Biotechnology Associates, Inc.)isolated from mice and counted using a hemocytometer prior to
two-color immunofluorescence analysis. Retroorbital venous plexus to generate a standard curve (Engel et al., 1995b; Sato et al., 1995).
The relative concentration of immunoglobulin in individual samplespuncture was utilized to obtain blood. Leukocytes (0.5 3 106 to 1 3
106) were stained at 48Cusing predeterminedoptimal concentrations was calculated by comparing the mean OD obtained for triplicate
wells to a semi-log standard curve of titrated standard antibodyof the test MAb for 20 min as described (Zhou et al., 1994). Blood
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using linear regression analysis. DNP- or TNP-specific antibody ti- Kiesel, S., and Nadler, L.M. (1986). HD39 (B3), a B lineage-restricted
antigen whose cell surface expression is limited to resting and acti-ters of sera were measured as above, except sample sera were
added to ELISA plates coated with DNP–bovine serum albumin (5 vated human B lymphocytes. J. Immunol. 136, 4470–4479.
mg/ml; Calbiochem-Novabiochem Corp.) or TNP–bovine serum al- Engel, P., Nojima, Y., Rothstein, D., Zhou, L.-J., Wilson, G.L., Kehrl,
bumin (Biosearch). J.H., and Tedder, T.F. (1993). The same epitope on CD22 of B lym-
phocytes mediates the adhesion of erythrocytes, T and B lympho-
Statistical Analysis cytes, neutrophils and monocytes. J. Immunol. 150, 4719–4732.
All data are shown as mean values 6 SD except when otherwise Engel, P., Wagner, N., Miller, A., and Tedder, T.F. (1995a). Identifica-
indicated. The Student’s t test was used to determine the level of tion of the ligand binding domains of CD22, a member of the immu-
significance of differences in sample means. The paired Student’s noglobulin superfamily that uniquely binds a sialic acid-dependent
t test was used to compare mean fluorescence channel numbers ligand. J. Exp. Med. 181, 1581–1586.
for gated populations of cells analyzed by flow cytometry. Pairs
Engel, P., Zhou, L.-J., Ord, D.C., Sato, S., Koller, B., and Tedder,were between samples from different mice that were stained in
T.F. (1995b). Abnormal B lymphocyte development, activation and
parallel and analyzed sequentially using the same flow cytometer
differentiation in mice that lack or overexpress the CD19 signal
parameter settings.
transduction molecule. Immunity 3, 39–50.
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